Skip to main content

Peer Review reports

From: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

Original Submission
7 Oct 2015 Submitted Original manuscript
8 Dec 2015 Author responded Author comments - Victor Lee
8 Nov 2015 Reviewed Reviewer Report - Chang-Hsien Lu
7 Nov 2015 Reviewed Reviewer Report - Yusuke Okuma
Resubmission - Version 2
8 Dec 2015 Submitted Manuscript version 2
22 Jan 2016 Author responded Author comments - Victor Lee
Resubmission - Version 3
22 Jan 2016 Submitted Manuscript version 3
6 Feb 2016 Author responded Author comments - Victor Lee
Resubmission - Version 4
6 Feb 2016 Submitted Manuscript version 4
Publishing
17 Feb 2016 Editorially accepted
24 Feb 2016 Article published 10.1186/s12885-016-2201-9

You can find further information about peer review here.

Back to article page
\